Bioengineers have developed microneedles that automatically adjust drug release based on reactive oxygen species levels in infected wounds. The dual-layer patch delivers doxorubicin for immediate bacterial killing, then releases resveratrol when oxidative stress peaks, promoting anti-inflammatory healing responses. Testing against S. aureus and E. coli showed significant bacterial inhibition while enhancing M2 macrophage polarization—the repair-focused immune state. This represents a sophisticated departure from static wound treatments that deliver fixed drug concentrations regardless of healing stage. Chronic wounds often cycle between bacterial overgrowth and excessive inflammation, requiring precisely timed interventions that current bandages cannot provide. The ROS-responsive mechanism mimics the body's natural healing cascade, potentially addressing the $25 billion chronic wound care market where 40% of diabetic ulcers fail standard treatment. However, the rat model data needs validation in human skin, which has different penetration characteristics and immune responses. The manufacturing complexity and cost of producing dual-layer microneedles with crosslinked polymer matrices may limit initial adoption. If scalable, this technology could fundamentally shift wound care from passive protection to active, adaptive therapy.